PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
(World News USA)

DGAP-News: PAION AG / Key word(s): Regulatory Approval 02.07.2020 / 20:09 The issuer is solely responsible for the content of this announcement. PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION - PAION will receive a milestone payment of EUR 15 million from Cosmo and tiered royalties on net sales ranging from 20% to 25% - Acacia, who will commercialize BYFAVOTM (remimazolam) in the U.S., is planning to launch in the second half of 2020 - Conference call hosted by Acacia scheduled for 9:00 am ET, Monday 6 July 2020 Aachen (Germany), 02 July 2020 - The specialty pharma company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock...